Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.
Dela sida
Sponsrat innehåll

Introducing Croda's Adjuvant Systems Platform

With over 80 years of experience our scientists deliver high quality adjuvants to meet your vaccine formulation needs today. Beyond today we want to meet your formulation needs of the future. Our extensive expertise in immunology and formulation of adjuvant systems means we can partner with you to develop the next generation of vaccines, adapting to your requirements. We use our manufacturing experience to turn novel technologies into commercial GMP products, driven by our purpose to use ‘smart science to improve lives™’

Our adjuvant portfolio 
We offer a diverse portfolio of technologies at the highest of production standards. With extensive experience in cGMP manufacturing, we manufacture high quality mineral adjuvants, and saponins:

1. PHAD is the first synthetic analogue of monophosphoryl lipid A (MPLA) derived from Salmonella minnesota. MPLA has been shown to be safe and effective in stimulating Th-1 type immune responses. Avanti developed PHAD as a synthetic alternative to the bacterial-derived MPLA, given its desirable vaccine design profile of low reactogenicity and high efficacy.

2. 3D-PHAD is part of our PHAD portfolio and is a 3-deacylated form of MPLA. Varying the number and positioning of acyl chains creates a variety of lipophile/hydrophile ratios that can be utilised by formulation scientists to better suit their lipid-delivery systems. It has been used in vaccine research to tackle the influenza virus and opioid overdose crisis.

3. 3D(6-acyl)-PHAD, has a unique chemical structure that consists of a hexapeptide modified with a pyridoxal-phosphate group and a fatty acid chain. To date, it has been used in vaccine research for renal cell carcinoma, human papillomaviruses, and hepatitis B virus.

4. . CAF01 is a fully synthetic liposome-based adjuvant system developed by Statens Serum Institut (SSI.) It is comprised of DDA, a cationic quaternary ammonium salt, and the glycolipid TDB. It is known for long-term protection and immunological memory, due to its power to elicit potent Th1 and Th17 responses. CAF01 is used in several ongoing clinical vaccine trials, including for tuberculosis, chlamydia, HIV, and malaria.

5. CAF09b is a liposomal adjuvant delivery system developed by Statens Serum Institut (SSI.) Fully synthetic, it is comprised of lipid surfactants (DDA and MMG) and the TLR3 agonist poly(I:C). CAF09b is known for its powerful capacity to stimulate cytotoxic T-cell responses, particularly if administered via an intraperitoneal route - making it an excellent candidate for cancer immunotherapy! 

6. Alhydrogel, aluminium hydrogels, have been used in a broad range of vaccines for several decades . Manufactured since 1939, they are used in many modern vaccines, such as for tetanus, anthrax, and meningitis, as well as in developmental vaccines, such as against SARS-CoV-2.

7. Adju-Phos is our aluminium phosphate gel that has been specifically developed for use as an adjuvant in vaccines. Adju-Phos has a net negative charge at neutral pH and effectively adsorbs positively charged antigens. Adju-Phos differentiates itself from Alhydrogel both chemically and structurally, both being amorphous aggregates of nanometre-size hydrous crystallites. Aluminium adjuvants are used in human vaccines for tetanus, diphtheria, pertussis, poliomyelitis, as well as hepatitis A and B.

8. QS 21 QS 21 is derived from the soap-bark tree (Quillaja saponaria Molina) native to South America. It is a specific fraction of our Quil-A™ saponin mixture, selected for its rich source of triterpenoid saponins, potent immunogenicity, and low reactogenicity. With amphiphilic properties, QS 21 can be formulated with lipids to dramatically reduce cell lysis. In turn, this allows for strong control of potential side effects in final formulations.

If you would like to learn more about immunostimulation and where adjuvant technology is headed listen to our webinar with Dr. Dennis Christensen on demand by copy and pasting the following title in your browser: Insight into immunostimulation - for better vaccine performance (NAMER/LATAM) (on24.com)

Croda Nordica AB
Geijersgatan 2B
216 18 Limhamn
Malmö stad
VAT nummer: SE5564796638



Sänd till en kollega